Manufacturer of Controlled Substances; Notice of Registration, 65660 [2010-27035]
Download as PDF
<![CDATA[
65660
Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices
by renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
small quantities of the above listed
controlled substance for distribution to
its customers for the purpose of
research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 27, 2010.
Dated: October 14, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–27037 Filed 10–25–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
emcdonald on DSK2BSOYB1PROD with NOTICES
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on July 9,
2010, Noramco, Inc., 1440 Olympic
Drive, Athens, Georgia 30601, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Schedule
Thebaine (9333) ...........................
Tapentadol (9780) ........................
II
II
The company plans to import
Thebaine (9333) analytical reference
standards for distribution to its
customers. The company plans to
VerDate Mar<15>2010
18:09 Oct 25, 2010
Jkt 223001
import an intermediate form of
Tapentadol (9780) to bulk manufacture
Tapentadol for distribution to its
customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 26, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 15, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–27032 Filed 10–25–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 21, 2009 and
published in the Federal Register on
October 28, 2009, (74 FR 55586),
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Tapentadol (9780, a basic class of
controlled substance listed in schedule
II.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
One comment objecting to the
granting of registration as a bulk
manufacturer of the basic class of
controlled substance listed to this
applicant was received. However, after
a thorough review of this matter, DEA
has concluded that the issues raised in
the comment and objection do not
warrant the denial of this application.
DEA has considered the factors in 21
U.S.C. 823(a) and determined that the
registration of Archimica, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Archimica, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: October 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–27035 Filed 10–26–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Steven B. Brown, M.D.; Revocation of
Registration
On May 13, 2010, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Show Cause and Immediate Suspension
of Registration (‘‘Order’’) to Steven B.
Brown, M.D. (‘‘Registrant’’), of Wilton
Manors and Pompano Beach, Florida.
The Order proposed the revocation of
Registrant’s DEA Certificates of
Registration, BB2972140 and
FB1490349, as well as the denial of any
pending applications for the renewal or
modification of both registrations, on
the ground that his ‘‘continued
registrations are inconsistent with the
public interest, as that term is defined
in 21 U.S.C. 823(f).’’ Order, at 1.
The Order alleged that Registrant
‘‘issued illegal prescriptions for
oxycodone, a Schedule II controlled
E:\FR\FM\26OCN1.SGM
26OCN1
]]>Agencies
[Federal Register Volume 75, Number 206 (Tuesday, October 26, 2010)]
[Notices]
[Page 65660]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27035]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated October 21, 2009 and published in the Federal
Register on October 28, 2009, (74 FR 55586), Archimica, Inc., 2460 W.
Bennett Street, Springfield, Missouri 65807-1229, made application by
letter to the Drug Enforcement Administration (DEA) to be registered as
a bulk manufacturer of Tapentadol (9780, a basic class of controlled
substance listed in schedule II.
The company plans to manufacture the listed controlled substance in
bulk for distribution to its customers.
One comment objecting to the granting of registration as a bulk
manufacturer of the basic class of controlled substance listed to this
applicant was received. However, after a thorough review of this
matter, DEA has concluded that the issues raised in the comment and
objection do not warrant the denial of this application.
DEA has considered the factors in 21 U.S.C. 823(a) and determined
that the registration of Archimica, Inc. to manufacture the listed
basic class of controlled substance is consistent with the public
interest at this time. DEA has investigated Archimica, Inc. to ensure
that the company's registration is consistent with the public interest.
The investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance
with 21 CFR 1301.33, the above named company is granted registration as
a bulk manufacturer of the basic class of controlled substance listed.
Dated: October 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-27035 Filed 10-26-10; 8:45 am]
BILLING CODE 4410-09-P
